Clinical trials, including crest and potomac, are exploring the role of immunotherapy in non-muscle-invasive bladder cancer. The effectiveness of current treatments, such as BCG, is being reevaluated, with some studies investigating combinations of BCG and other immunotherapies. The outcomes of these trials may lead to a redefinition of immunotherapy's role in treating this type of cancer.